相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study
Gunnar Toft et al.
JOURNAL OF NEPHROLOGY (2020)
Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Tadao Akizawa et al.
ADVANCES IN THERAPY (2019)
Roxadustat and Anemia of Chronic Kidney Disease
Joshua Kaplan
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis
N. Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
N. Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States
Rajiv Saran et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2019)
Roxadustat in the treatment of anaemia in chronic kidney disease
Lucia Del Vecchio et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review
Tadao Akizawa et al.
THERAPEUTIC APHERESIS AND DIALYSIS (2018)
Anemia and mortality in patients with nondialysis-dependent chronic kidney disease
Heide A. Stirnadel-Farrant et al.
BMC NEPHROLOGY (2018)
The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease
Hongzhen Zhong et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015)
Haesuk Park et al.
BMC NEPHROLOGY (2018)
Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of Anemia
Ping Liu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
Nan Chen et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2017)
Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond
Norishi Ueda et al.
CURRENT MEDICINAL CHEMISTRY (2017)
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD
Nupur Gupta et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2017)
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
Anatole Besarab et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6-to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study
Robert Provenzano et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing
Angelo Karaboyas et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality
George R. ' Bailie et al.
KIDNEY INTERNATIONAL (2015)
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
Anatole Besarab et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)
Effect of Facility-Level Hemoglobin Concentration on Dialysis Patient Risk of Transfusion
Allan J. Collins et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD
Alan S. Kliger et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2013)
Chronic kidney disease: global dimension and perspectives
Vivekanand Jha et al.
LANCET (2013)
Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents
Tetsuhiro Tanaka et al.
EXPERIMENTAL CELL RESEARCH (2012)
Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis
Qingdu Liu et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Review: Cochrane handbook for systematic reviews for interventions, Version 5.1.0, published 3/2011. Julian P.T. Higgins and Sally Green, Editors
Jonathan J. Shuster
Research Synthesis Methods (2011)
Two to Tango: Regulation of Mammalian Iron Metabolism
Matthias W. Hentze et al.
CELL (2010)
Regulation of the HIF-1α Level Is Essential for Hematopoietic Stem Cells
Keiyo Takubo et al.
CELL STEM CELL (2010)
Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes.
Scott D. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Evidence for a Lack of a Direct Transcriptional Suppression of the Iron Regulatory Peptide Hepcidin by Hypoxia-Inducible Factors
Melanie Volke et al.
PLOS ONE (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes
Lynda A. Szczech et al.
KIDNEY INTERNATIONAL (2008)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)
Carole Peyssonnaux et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Hepcidin - central regulator of iron metabolism
Valeriu Atanasiu et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
Correction of anemia with epoetin alfa in chronic kidney disease
Ajay K. Singh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Normalization of hemoglobin level in patients with chronic kidney disease and anemia
Tilman B. Drueke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
T Ganz
BLOOD (2003)
分享论文
